Peptide Merchant Account for Research-Only Businesses
Stable credit card processing for research peptide suppliers. Manual underwriting, dedicated MIDs, and bank relationships built for the long term, not automated approvals that terminate six months in.
Payment Infrastructure Built for Research Peptide Businesses
Every feature below is standard across our peptide business merchant accounts. Not an upgrade tier.
Credit Card Processing
Visa and Mastercard credit and debit processing. Each card network confirmed with the acquiring bank per compound before your account goes live. Not a shared aggregator account.
Crypto & ACH Settlement
Cryptocurrency and ACH bank transfer settlement available. Preferred by international peptide merchants who require alternative payout options.
Embedded Checkout
Payments processed directly on your site. No redirects, no third-party checkout pages. Works with Shopify, WooCommerce, and custom storefronts.
Fast Settlement Options
T+1 payout available for established accounts. T+3 or weekly for accounts building processing history. Settlement schedule confirmed before go-live.
Multi-Bank Setup
Access to 30+ acquiring institutions. Multi-MID arrangements available for volume redundancy and improved payment continuity.
Reserve Optimization
Reserve percentage negotiated individually and confirmed in writing at approval. Rolling release structure for merchants with established processing history.
CERF provides payment processing for research-only peptide businesses operating in compliance with applicable law. All merchants are required to maintain clear research-only disclaimers on their website, comply with applicable labelling standards, and ensure their business model is structured for research supply only. CERF does not support businesses selling peptides for human consumption or making therapeutic claims.
Why Peptide Businesses Get Shut Down
Card networks assess risk at the category level. Research peptide businesses receive an elevated classification by default, applied to the product type rather than the individual business. Processors without specific underwriting frameworks for this category apply blanket restrictions across the board. A clean processing history does not change the classification.
A specialist peptide payment processor provides a dedicated account specifically underwritten for research peptide businesses. Unlike mainstream processors, the acquiring bank reviews your business before you go live, so fees, reserve terms, and settlement schedules are agreed upfront. There are no post-approval surprises.
Approved in 20 minutes. Payments flow normally. Revenue grows. Six months later, an automated review flags the business.
Peptide account terminated. No appeal. No processing.
This is not a manual decision. It is an automated flag triggered by the merchant category, transaction patterns, or a product name match against the processor's restricted list. PayPal and Square apply the same restrictions.
CERF is a specialist peptide payment processor for research-only businesses: a dedicated merchant account with a specialist acquiring bank, not a payment facilitator account subject to automated closures.
Traditional Processors vs CERF
Why mainstream processors are not a long-term solution for high-risk peptide payment processing.
| Traditional Processor | CERF | |
|---|---|---|
| Underwriting | Automated, 20 minutes | Manual, reviewed before approval |
| Peptide businesses | Explicitly prohibited | Supported, core underwritten category |
| When risk is assessed | Six months in, during a volume review | Before your account opens |
| Account stability | Terminated without notice | Dedicated MID, not a shared account |
| Reserve | Funds held without warning, no formal terms | Reserve agreed in writing at approval |
| LegitScript required | Required | Not required for research-only businesses |
| Volume capacity | Flagged or terminated at scale | $5M+/month. Structured for large-scale peptide operations. |
How CERF Underwrites Peptide Merchant Accounts
Risk is front-loaded. Every material decision is made before your account opens, not six months later during an automated review.
Manual Underwriting
Every application reviewed by a person, not an automated risk model. We assess your business individually against acquiring requirements specific to the peptide category.
Per-Compound Review
Each compound confirmed with the acquiring bank before your account opens. No compounds are assumed. Each one is explicitly approved as part of the underwriting process.
Front-Loaded Risk Assessment
Risk is assessed before go-live, not six months in during a volume review. If there is an issue with your business model or website, you find out before your account is active.
Pre-Launch Guidance
If your website needs changes to meet acquiring requirements, you receive specific recommendations before go-live, not a rejection after the fact.
Multi-Bank Access
Relationships with 30+ acquiring institutions, not a single peptide payment processor dependency. Redundancy built in from the start, with multi-MID setups available for higher-volume merchants.
Terms Agreed Upfront
Reserve percentage, settlement schedule, and processing fee confirmed in writing before approval. No surprises after you go live.
Merchants terminated by Stripe or PayPal are sometimes added to the MATCH list. A MATCH listing does not automatically disqualify a peptide business from specialist acquiring. CERF reviews each case individually. Most compliant research-only businesses with prior terminations are approvable once the processing history and termination context are assessed in full.
Peptide Businesses We Support
CERF works with the full range of research peptide business models: direct-to-consumer ecommerce, wholesale distribution, specialty catalogues, and established high-volume operations processing $5M+ monthly.
Direct-to-Consumer Peptide Stores
Research peptide ecommerce brands selling through Shopify, WooCommerce, or custom websites. Embedded checkout, descriptor management, and chargeback monitoring included.
High-Volume Peptide Operations
Established research peptide businesses processing $5M+ monthly. Multi-MID structure, dedicated acquiring relationships, and reserve optimisation for operations where payment continuity directly impacts revenue.
Wholesale Peptide Suppliers
Bulk research-only peptide supply with B2B ordering, recurring buyers, and high-ticket transactions. Multi-MID structure available for volume distribution across multiple acquiring relationships.
GLP-1 & Weight Management Peptide Brands
Businesses focused on research-only GLP-1 related products. Semaglutide merchant processing and tirzepatide research accounts assessed individually by jurisdiction and product positioning at underwriting.
Specialty Peptide Catalogues
Merchants offering broad research peptide catalogues including BPC-157, TB-500, CJC-1295, Ipamorelin, and related compounds. Per-compound confirmation included in underwriting.
Cross-Border & International Peptide Merchants
Research peptide businesses shipping to the US, EU, UK, and international markets simultaneously. Multi-currency acquiring and jurisdiction-specific compliance for merchants operating across borders.
Research and wellness brands carrying nutraceutical product lines alongside peptide compounds may also require a nutraceuticals merchant account with a separate MCC configuration. Businesses offering subscription-based research programmes should review our subscription billing merchant account structure before applying.
BPC-157, TB-500 and Other Research Peptide Categories
CERF processes the following research peptide categories. Each compound, including BPC-157 merchant account applications and GLP-1 compounds, is confirmed individually with the acquiring bank before the account goes live. Businesses seeking a GLP-1 payment processor for peptides are assessed individually based on jurisdiction and product positioning.
Peptide Merchant Account Requirements and Documentation
The most common reason peptide merchants are declined is non-compliant website copy, not their product category. If your site clearly positions products for research use only and avoids health claims, approval through a specialist acquirer is typically straightforward.
Legal entity and jurisdiction confirmation. We work with US, UK, EU, and Canadian entities.
3 months of business bank statements. For new businesses, a clean statement is acceptable.
Previous processing statements, chargeback ratios, and termination context if applicable. Prior termination does not disqualify you.
Full product list or SKU catalogue. Each compound is confirmed with the acquiring bank individually.
Research-only disclaimers on product pages, checkout, and terms of service. No therapeutic claims anywhere on the site.
Labels confirming research-use-only positioning. No health claims, no therapeutic language, no dosage guidance for human use.
How the Application Works
Three structured stages from application to active processing. Every decision is made before your account goes live.
Submit Your Application
Complete the contact form with your business details, product category, and estimated monthly volume. A peptide account specialist will review your submission and be in touch to discuss next steps.
Compliance and Underwriting Review
We review your website, disclaimers, chargeback history, compound list, and processing setup. For most research peptide merchants, this stage takes up to 5 business days.
Account Activation
Once approved, your peptide payment gateway connects to your checkout. We support Shopify, WooCommerce, and custom integrations. Processing begins following gateway integration and final bank confirmation.
Peptide Merchant Account Payment Terms
All fees and terms are disclosed before signing. No surprises after approval.
| Term | What to Expect |
|---|---|
| Processing fee | 5% to 8.5% depending on acquiring bank, product category, and chargeback history |
| Rolling reserve | 5% to 10% of monthly volume for the first 6 months, released on a rolling basis |
| Settlement | T+1 for established accounts; T+3 or weekly for new accounts building processing history |
| Contract term | Typically 12 months |
| Approval timeline | Up to 5 business days for research peptide merchants |
| Setup fee | None |
| Accepted cards | Visa, Mastercard and major debit cards; ACH bank transfers available |
Reserve structure and settlement timing have a larger practical impact on cash flow than the headline processing rate. Ask any processor you evaluate to confirm these in writing before you sign.
Common Questions About Peptide Merchant Accounts
The Growing Demand for Peptide Payment Processing
The global peptide therapeutics market was valued at $52.6 billion in 2025 and continues to grow as pharmaceutical development and consumer interest in peptide-based compounds accelerates. The driver most visible to payment processors is the GLP-1 category: semaglutide now generates over 1.5 million monthly searches in the United States alone, compared to approximately 74,000 for BPC-157, one of the most widely searched research peptides. That gap is closing.
For payment processors, this growth creates a specific challenge. The same consumer awareness driving demand also increases the scrutiny applied to peptide businesses by card networks and acquiring banks. Merchants who grew steadily through 2022 and 2023 increasingly found their accounts reviewed, restricted, or terminated as processor risk models were updated to reflect the higher-profile nature of the category.
In February 2026, fourteen of nineteen peptides previously under FDA compounding restrictions were reclassified back to Category 1 status, reinstating their availability through licensed compounding pharmacies. This current regulatory landscape for peptide compounding reflects the ongoing evolution of the space and underscores why payment infrastructure built on static risk models consistently fails peptide merchants over time. Stable processing in this vertical requires a processor who tracks these changes, not one who discovers them after terminating an account.
CERF has been building payment processing for peptides since 2022 and has adapted its underwriting alongside these changes, working with acquiring partners who have developed specific frameworks for research-only peptide merchants rather than treating them as generic nutraceutical businesses.